MRK
MRNA
From vaccine darling to “what’s next?”
Moderna has spent the last few years trying to answer the same awkward investor question: once the COVID cash faucet slowed, what was supposed to keep the lights on? That’s a tough place to be when your pandemic-era revenue boom went from roughly $20 billion in 2022 to basically a much smaller, much less glamorous number a few years later.
Enter the cancer plot twist
This week, Moderna and Merck said their personalized mRNA cancer vaccine hit the primary endpoints in a Phase 3 melanoma trial. Translation: the science didn’t just look cute in a lab coat — it cleared a major late-stage test.
Why that matters:
- It’s the first mRNA-based cancer treatment to show Phase 3 success.
- It gives Moderna a real, grown-up argument that its platform can do more than fight viruses.
- It could open the door to a much bigger oncology pipeline if the same approach keeps working in other cancers.
Why investors suddenly care again
For Moderna shareholders, this is more than a single trial result. It’s a narrative reboot. If the data hold up and the company can keep expanding into lung, bladder, and kidney cancer, Moderna may finally have the kind of second act that justifies a premium beyond its pandemic history.
That said, don’t break out the confetti cannons yet. Phase 3 wins are great, but they’re not the same thing as a blockbuster commercial franchise. Investors will still want the detailed data, the next readouts, and eventually evidence that doctors and payers actually want to use it.
Big picture: COVID made Moderna famous. Cancer could be what makes it matter again.